Tweet
HC Wainwright set a $30.00 price target on Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Monday. The brokerage currently has a buy rating on the biopharmaceutical company's stock.
Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed a buy rating and issued a $36.00 target price on shares of Abeona Therapeutics in a research report on Saturday, August 11th. Maxim Group reaffirmed a buy rating and issued a $35.00 target price on shares of Abeona Therapeutics in a research report on Friday, August 10th. BidaskClub raised Abeona Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 2nd. ValuEngine raised Abeona Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. Finally, Zacks Investment Research raised Abeona Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Abeona Therapeutics has an average rating of Buy and an average target price of $28.30. Get Abeona Therapeutics alerts:
NASDAQ ABEO opened at $13.70 on Monday. The stock has a market capitalization of $645.72 million, a price-to-earnings ratio of -20.76 and a beta of 1.37. Abeona Therapeutics has a 1-year low of $7.45 and a 1-year high of $22.75. Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The firm had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. equities research analysts anticipate that Abeona Therapeutics will post -0.71 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Abeona Therapeutics by 47.7% in the 2nd quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company's stock valued at $113,509,000 after buying an additional 2,291,016 shares during the period. BlackRock Inc. boosted its stake in shares of Abeona Therapeutics by 16.6% in the 2nd quarter. BlackRock Inc. now owns 2,184,506 shares of the biopharmaceutical company's stock valued at $34,951,000 after buying an additional 311,034 shares during the period. Millennium Management LLC boosted its stake in shares of Abeona Therapeutics by 5.3% in the 2nd quarter. Millennium Management LLC now owns 964,839 shares of the biopharmaceutical company's stock valued at $15,437,000 after buying an additional 48,583 shares during the period. Nexthera Capital LP boosted its stake in shares of Abeona Therapeutics by 69.6% in the 2nd quarter. Nexthera Capital LP now owns 626,804 shares of the biopharmaceutical company's stock valued at $10,029,000 after buying an additional 257,304 shares during the period. Finally, PointState Capital LP purchased a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $9,210,000. Institutional investors and hedge funds own 69.29% of the company's stock.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B